Sign inJoin waitlistJoin the waitlist

Breelyn Wilky

Lead · University of Colorado School of Medicine

Credentials: · · · · ·

History

University of Colorado School of Medicine
Present

Medical Oncology
2009–2011
Internal Medicine
2006–2009
Rutgers, Robert Wood Johnson Medical School
2002–2006

Research

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
The Lancet Oncology · 2019 · First of 15 authors · Corresponding · 331 citations
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
The Lancet · 2024 · 258 citations
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
New England Journal of Medicine · 2023 · 219 citations

Jonathan Trent
20 papers
Andrew Rosenberg
12 papers
Ty Subhawong
10 papers
Vaia Florou
10 papers · 6 as a fellow
David Loeb
9 papers
Darcy Kerr
7 papers
BT
Brian Van Tine
5 papers
George Demetri
5 papers
WT
William Tap
5 papers
AM
Alessandra Maleddu
4 papers · 2 as a fellow
Andrea Bullock
4 papers
Andrew Wagner
4 papers

Clinical trials

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
Principal investigator · Recruiting · Phase 2
University of Colorado, Denver
2026–2029
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Principal investigator · Active not recruiting · Phase 2
University of Colorado, Denver
2020–2027
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2030
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032